Evidence map›Paper›PMID 40234276›Full record

ArticleMedical molecular morphology2026

Immunohistochemical investigation of the transcription factor PROX1 emphasizing on neuroendocrine neoplasms.

Kanata Kojima, Kouhei Sakurai, Tatsuya Ando, Yasuhiro Sakai, Mako Ochiai, Taku Kato, Hiroyasu Ito

Abstract read
PubMed Publisher
In one paragraph

Article in Medical molecular morphology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kanata KojimaDepartment of Clinical Laboratory, Fujita Health University Hospital, Toyoake, Aichi, 470-1192, Japan.
Kouhei SakuraiDepartment of Joint Research Laboratory of Clinical Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. kouhei.sakurai@fujita-hu.ac.jp.ORCID http://orcid.org/0000-0003-2428-0310
Tatsuya AndoDepartment of Joint Research Laboratory of Clinical Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Yasuhiro SakaiDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, 431-3192, Japan.
Mako OchiaiDepartment of Clinical Laboratory, Fujita Health University Hospital, Toyoake, Aichi, 470-1192, Japan.
Taku KatoDepartment of Joint Research Laboratory of Clinical Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Hiroyasu ItoDepartment of Clinical Laboratory, Fujita Health University Hospital, Toyoake, Aichi, 470-1192, Japan.

Funding

Japan Society for the Promotion of Science 18K09545Japan Society for the Promotion of Science 24K12892
6 · The paper itself

Abstract

Prospero homeobox protein 1 (PROX1) is aberrantly expressed in tumors, including neuroendocrine neoplasms (NENs); however, the detailed expression pattern remains elusive. This study aimed to immunohistochemically assess PROX1 expression. Immunohistochemistry (IHC) for PROX1 was performed on tissue microarrays of normal tissues (n = 107), NENs (n = 152) (small cell lung carcinoma [SCLC], lung carcinoid [LC], gastroenteropancreatic-NEN [GEP-NEN], esophageal neuroendocrine carcinoma [ENEC], medullary thyroid carcinoma [MTC], neuroblastoma [NB], and pheochromocytoma [PHEO]), and non-NENs (n = 469). In normal tissues, PROX1 was expressed in lymphatic endothelial cells and a subset of epithelial cells in the gastrointestinal tract and the distal convoluted tubules. In NENs, the positive expression was observed in the nucleus of tumor cells in 19/26 SCLC (73.1%), 13/16 LC (81.3%), 10/15 GEP-NEN (66.7%), 2/2 ENEC (100%), 17/43 MTC (39.5%), 1/25 NB (4.0%), and 0/25 PHEO (0%). Although PROX1 was negative in many non-NENs, our analysis revealed high expression in certain cases with medulloblastoma and one case with juvenile granulosa cell tumor. PROX1 was expressed in specific cases with epithelial NENs and some cases with non-NENs. Analysis of PROX1 should provide insights into the molecular characteristics of distinct tumors.

Indexed as

Homeodomain ProteinsNeuroendocrine TumorsTumor Suppressor ProteinsBiomarkers, TumorCarcinoma, NeuroendocrineFemaleHumansImmunohistochemistryProspero-Related Homeobox 1 ProteinTissue Array AnalysisBiomarkers, TumorHomeodomain ProteinsProspero-Related Homeobox 1 ProteinTumor Suppressor ProteinsImmunohistochemistryNeuroendocrine neoplasmsPROX1Transcription factor

Identifiers

PMID40234276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.